Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Chief Commercial Officer | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.94 · Expires 2036-05-05 | Direct | 120,000 |
Reported balance
After 2026-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 120,000 · Balance 120,000 F1: This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARINUS PHARMACEUTICALS, INC.
Report date February 07, 2025 · Filed February 11, 2025
Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-07 · Disposition to issuer · Disposed 18,778 · Balance 48,628 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Row 2 · 2025-02-11 · Disposition to issuer · Disposed 48,628 · Balance 0 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2: Represents 48,628 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-11 · Disposition to issuer · Disposed 49,125 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-11 · Disposition to issuer · Disposed 98,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-11 · Disposition to issuer · Disposed 78,188 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-11 · Disposition to issuer · Disposed 57,900 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2031-01-15 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2030-11-09 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-11 · Disposition to issuer · Disposed 128,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
F2: Represents 48,628 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 16:35 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001934412-26-000006 · wk-form4_1778171726.xml · derivative · entry 1 Shafer Christina · CIK 0001934412 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-05 F1 · derivative.exercise_date: This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 128,000 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 8 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,000 shares Expires 2030-11-09 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 7 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-01-15 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 57,900 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 6 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,900 shares Expires 2032-02-04 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,188 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 5 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,188 shares Expires 2033-01-26 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 98,250 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 4 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,250 shares Expires 2034-01-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 49,125 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · derivative · entry 3 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,125 shares Expires 2034-06-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 48,628 | $0.55 | $26,745.40 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · nonDerivative · entry 2 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2 · shares: Represents 48,628 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 09:12 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 18,778 | $0.55 | $10,327.90 |
DisclosureSEC source: 0001104659-25-011240 · tm255946-3_4seq1.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,628 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 16:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 3,820 | $1.14 | $4,354.80 |
DisclosureSEC source: 0001415889-24-020899 · form4-08072024_040812.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,406 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:22 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 49,125 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-017632 · form4-06202024_080637.xml · derivative · entry 2 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,125 Underlying: Common Stock · 49,125 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:22 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 10,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017632 · form4-06202024_080637.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,226 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 2,153 | $9.56 | $20,582.68 |
DisclosureSEC source: 0001415889-24-004782 · form4-02222024_040209.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,308 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.08 to $9.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:21 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 98,250 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001415889-24-001594 · form4-01192024_090124.xml · derivative · entry 2 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,250 Underlying: Common Stock · 98,250 shares Expires 2034-01-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:21 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 21,835 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001594 · form4-01192024_090124.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,461 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2025, the second installment vesting on February 15, 2026, and the third installment vesting on February 15, 2027, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| August 08, 2023 Filed Aug 8, 2023 21:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 11 | $8.93 | $98.23 |
DisclosureSEC source: 0001415889-23-011952 · form4-08082023_090810.xml · nonDerivative · entry 2 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,626 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F3 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | SaleCommon Stock | 2,385 | $9.52 | $22,705.20 |
DisclosureSEC source: 0001415889-23-011952 · form4-08082023_090810.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,637 F1 · kind: The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.35 to $9.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:30 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 78,188 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001415889-23-001566 · form4-01302023_090106.xml · derivative · entry 2 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,188 Underlying: Common Stock · 78,188 shares Expires 2033-01-26 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:30 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 17,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001566 · form4-01302023_090106.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,022 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in three equal installments, with the first installment vesting on February 15, 2024, the second installment vesting on February 15, 2025, and the third installment vesting on February 15, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 07:43 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Tax withholdingCommon Stock | 1,505 | $4.70 | $7,073.50 |
DisclosureSEC source: 0001104659-22-117734 · tm2230313-1_4seq1.xml · nonDerivative · entry 1 Shafer Christina · CIK 0001934412 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,647 F1 · kind: Represents 1,505 shares withheld to cover taxes associated with the November 9, 2022 vesting of 5,000 restricted stock awards. F1 · shares: Represents 1,505 shares withheld to cover taxes associated with the November 9, 2022 vesting of 5,000 restricted stock awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.